• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bayer A G Ord (OP:BAYZF)

    50.03 -5.15 (-9.33%)
    Delayed Quote Updated: 1:04 PM EDT, Oct 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,150
    Open 51.25
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 55.18
    Today's Range 50.03 - 51.28
    52wk Range 30.00 - 61.38
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle
    From Bayer
    Via Business Wire
    News headline image
    MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option
    From Bayer
    Via Business Wire

    Performance

    YTD
    +11.4%
    +11.4%
    1 Month
    -11.6%
    -11.6%
    3 Month
    -9.4%
    -9.4%
    6 Month
    +7.2%
    +7.2%
    1 Year
    +51.0%
    +51.0%

    More News

    Read More
    News headline image
    U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer
    From Bayer
    Via Business Wire
    News headline image
    Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
    From Bayer
    Via Business Wire
    News headline image
    Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
    From Bayer
    Via Business Wire
    News headline image
    U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
    From Bayer
    Via Business Wire
    News headline image
    BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
    From Bayer
    Via Business Wire
    News headline image
    Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026
    From Bayer
    Via Business Wire
    News headline image
    Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
    From Bayer
    Via Business Wire
    News headline image
    One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin
    From Bayer
    Via Business Wire
    News headline image
    New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
    From Bayer
    Via Business Wire
    News headline image
    Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
    From Bayer
    Via Business Wire
    News headline image
    Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming
    From Bayer
    Via Business Wire
    News headline image
    The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials
    From Bayer
    Via Business Wire
    News headline image
    Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart
    From Bayer
    Via Business Wire
    News headline image
    Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon
    From Bayer
    Via Business Wire
    News headline image
    Bayer and Iambic Collaborate to Advance Drug Discovery with AI
    From Bayer
    Via Business Wire
    News headline image
    Bayer Completes Acquisition of Perfuse Therapeutics
    From Bayer
    Via Business Wire
    News headline image
    Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions
    From Bayer
    Via Business Wire
    News headline image
    Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business
    From Bayer
    Via Business Wire
    News headline image
    Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth
    From Bayer
    Via Business Wire
    News headline image
    Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
    From Bayer
    Via Business Wire
    News headline image
    Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
    From Bayer
    Via Business Wire

    Frequently Asked Questions

    Is Bayer A G Ord publicly traded?
    Yes, Bayer A G Ord is publicly traded.
    What exchange does Bayer A G Ord trade on?
    Bayer A G Ord trades on the OTC Traded
    What is the ticker symbol for Bayer A G Ord?
    The ticker symbol for Bayer A G Ord is BAYZF on the OTC Traded
    What is the current price of Bayer A G Ord?
    The current price of Bayer A G Ord is 50.03
    When was Bayer A G Ord last traded?
    The last trade of Bayer A G Ord was at 10/01/26 01:04 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.